We also analyzed long-term survival (LTS; defined as ≥18-month OS) ( 27 ) and found a nonsignificant trend toward higher NOTCH1 expression in LTS compared with non-LTS patients in the atezolizumab but not in the placebo arm ( Supplemental Figure 2 ).
← all excerpts
NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING.
1
—
—